Related Experiment Video
Updated: Jan 23, 2026
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Nanovaccines for cancer immunotherapy
Yu Zhang1,2, Shuibin Lin1, Xiang-Yang Wang3,4,5
1Department of Rehabilitation Medicine, Center for Translational Medicine, Precision Medicine Institute, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Abstract:
The past few decades have witnessed the booming field of cancer immunotherapy. Cancer therapeutic vaccines, either alone or in combination with other immunotherapies such as adoptive cell therapy or immune checkpoint blockade therapy, are an attractive class of cancer immunotherapeutics. However, cancer vaccines have thus far shown suboptimal efficacy in the clinic. Nanomedicines offer unique opportunities to improve the efficacy of these vaccines. A variety of nanoplatforms have been investigated to deliver molecular or cellular or subcellular vaccines to target lymphoid tissues and cells, thereby promoting the potency and durability of anti-tumor immunity while reducing adverse side effects. In this article, we reviewed the key parameters and features of nanovaccines for cancer immunotherapy; we highlighted recent advances in the development of cancer nanovaccines based on synthetic nanocarriers, biogenic nanocarriers, as well as semi-biogenic nanocarriers; and we summarized newly emerging types of nanovaccines, such as those based on stimulator of interferon genes agonists, cancer neoantigens, mRNA vaccines, as well as artificial antigen-presenting cells. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
Insights
Cancer nanovaccines show promise for improving immunotherapy efficacy. These nanomedicines deliver vaccines to target cells, enhancing anti-tumor immunity and reducing side effects.
Area of Science:
- Nanomedicine
- Cancer Immunotherapy
- Vaccine Technology
Background:
- Cancer immunotherapy has advanced significantly, with therapeutic vaccines being a key focus.
- Current cancer vaccines often exhibit suboptimal clinical efficacy.
- Nanomedicines present a promising strategy to enhance vaccine performance.
Purpose of the Study:
- To review key parameters and features of nanovaccines for cancer immunotherapy.
- To highlight advances in nanovaccine development using various nanocarrier platforms.
- To summarize emerging nanovaccine types and their potential.
Main Methods:
- Review of recent literature on cancer nanovaccines.
- Categorization of nanovaccines based on synthetic, biogenic, and semi-biogenic nanocarriers.
- Discussion of novel nanovaccine approaches including STING agonists, neoantigens, mRNA, and artificial antigen-presenting cells.
Main Results:
- Nanoplatforms can effectively deliver vaccines to lymphoid tissues, boosting anti-tumor immunity.
- Diverse nanocarrier systems (synthetic, biogenic, semi-biogenic) are being explored for cancer nanovaccines.
- Emerging nanovaccine strategies show potential for improved therapeutic outcomes.
Conclusions:
- Nanomedicine offers a powerful approach to overcome limitations in current cancer vaccine efficacy.
- Advancements in nanocarrier design and novel vaccine modalities are expanding the potential of cancer nanovaccines.
- Cancer nanovaccines hold significant promise for enhancing anti-tumor immune responses and reducing adverse effects.
Related Concept Videos
01:27Tumor Immunotherapy
02:18Cancer
02:12What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
02:59Cancer Prevention
Some...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...